新型口服抗凝药用于冠状动脉支架置入术后抗栓效果和出血事件观察

Anti-thrombosis effect and bleeding event observation after new oral anticoagulant for coronary stent implantation

目的 探究新型口服抗凝药达比加群酯胶囊用于冠状动脉支架植入术(CSI)后的抗栓效果和不良反应发生情况.方法 选取我院收治的需CSI治疗的患者104例,随机分为实验组(52例)和对照组(52例),实验组术后患者服用达比加群酯胶囊,对照组服用华法林抗栓.比较两组患者术后抗栓效果和出血事件发生率.结果 血栓弹力图数据,实验组反应时间和凝血时间显著高于对照组(P<0.05),最大幅度显著低于对照组(P<0.05);术后12个月,实验组心血管事件发生率显著低于对照组(X2=8.735,P<0.05),实验组出血事件发生率显著低于对照组(X2=8.509,P<0.05).结论 新型口服抗凝药达比加群酯可有效预防患者CSI术后血栓形成,且出血风险较低,可优先使用.

Objective To explore the antithrombotic effect and adverse reactions of the new oral anticoagulant dabigatran etexilate capsules after coronary stenting(CSI).Method A total of 104 patients requiring CSI treatment were randomly divided into experimental group(52 cases)and control group(52 cases).In the experimental group,patients received dabigatran etexilate capsules,and the control group received warfarin antithrombotic.The antithrombotic effect and the incidence of bleeding events were compared between the two groups.Result The thromboelastography data,the reaction time and clotting time of the experimental group were significantly higher than the control group(P<0.05),the maximum amplitude was significantly lower than the control group(P<0.05).The 12-month postoperatively,the incidence of cardiovascular events in the experimental group was significant.The incidence of bleeding events in the experimental group was significantly lower than that in the control group(X^2=8.509,P<0.05).Conclusion The new oral anticoagulant dabigatran etexilate can effectively prevent thrombosis after CSI in patients with low risk of bleeding and can be used preferentially.